FDA advisers nix Cytokinetics' heart failure med, rejecting argument for subgroup use

FDA advisers nix Cytokinetics' heart failure med, rejecting argument for subgroup use

Submitted by admin on December 13, 2022 - 11:56pm
Source: 
Fierce Biotech
News Tags: 
FDA
Cytokinetics
heart failure
Omecamtiv Mecarbil
Headline: 
FDA advisers nix Cytokinetics' heart failure med, rejecting argument for subgroup use
snippet: 

FDA advisers elected to not recommend Cytokinetics heart failure med, voting eight to three that the risks of omecamtiv mecarbil outweigh its potential benefits. 

Do Not Allow Advertisers to Use My Personal information